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Abstract
Background: With the introduction of increasingly powerful mass spectrometry (MS) techniques
for clinical research, several recent large-scale MS proteomics studies have sought to characterize
the entire human plasma proteome with a general objective for identifying thousands of proteins
leaked from tissues in the circulating blood. Understanding the basic constituents, diversity, and
variability of the human plasma proteome is essential to the development of sensitive molecular
diagnosis and treatment monitoring solutions for future biomedical applications. Biomedical
researchers today, however, do not have an integrated online resource in which they can search
for plasma proteins collected from different mass spectrometry platforms, experimental protocols,
and search software for healthy individuals. The lack of such a resource for comparisons has made
it difficult to interpret proteomics profile changes in patients' plasma and to design protein
biomarker discovery experiments.
Description: To aid future protein biomarker studies of disease and health from human plasma,
we developed an online database, HIP2 (Healthy Human Individual's Integrated Plasma Proteome).
The current version contains 12,787 protein entries linked to 86,831 peptide entries identified
using different MS platforms.
Conclusion:  This web-based database will be useful to biomedical researchers involved in
biomarker discovery research. This database has been developed to be the comprehensive
collection of healthy human plasma proteins, and has protein data captured in a relational database
schema built to contain mappings of supporting peptide evidence from several high-quality and high-
throughput mass-spectrometry (MS) experimental data sets. Users can search for plasma protein/
peptide annotations, peptide/protein alignments, and experimental/sample conditions with options
for filter-based retrieval to achieve greater analytical power for discovery and validation.
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Background
A surge of interest in defining molecular biomarkers of
health and disease from human plasma has recently
emerged with the recent launch of the pilot Plasma Pro-
teome Project (PPP) by the Human Proteome Organiza-
tion (HUPO) [1]. The easy clinical access and processing
of plasma samples, and the abundance of proteins as well
as metabolites that may collectively define a person's
health status, have made human plasma the top choice
among bio-fluids for future clinical molecular diagnostic
applications. The fluctuating nature of blood from differ-
ent individuals, huge dynamic protein concentration
ranges (up to 1012), and the protein detection limits of
most MS platforms, have made the plasma proteome elu-
sive to define. Many proteomics researchers even believe
that the current "plasma proteome" observed by a single
shotgun MS experiment is analogous to a stochastic sam-
pling of the human proteome, with low run-to-run con-
sistencies and inherent detection biases peculiar to each
type of MS platform [2]. Even when used for healthy indi-
vidual plasma, with multi-dimensional separations and
advanced bioinformatics search software tools, proteins
identified in different shotgun MS/MS plasma proteomics
experiments are often inconsistent with each other except
for the most abundant proteins. To overcome the poor
coverage, potential bias, and complementary nature of
each experimental measurement of the human plasma
proteome, it is necessary for biomedical researchers to col-
lect and assess all reliable publicly-available plasma pro-
tein data sets generated from different MS analytical and
computational platforms for healthy individuals. A com-
prehensive integrated resource of the human plasma pro-
teins for healthy individuals, currently missing in the field
of clinical proteomics, would enable researchers to under-
stand the basic constituents, diversity, and variability of
the human plasma proteome. Such a resource would pro-
vide a high amount of comparative power for interpreting
proteomics profile changes in patients' plasma, and may
supplement or compensate for limitations and biases
associated with the set of controls for a given study. It
would also improve the ability for finding protein
biomarkers that are known to occur in healthy human
plasma for instances where a protein is differentially
expressed in a patient sample related to the quantities
observed in the study control.
Although multiple projects to profile the human plasma
proteome have been attempted, including PeptideAtlas,
GPMO, HUPO PPP, and several recent publications [3-6],
an unaddressed need has been for a compiled, central
repository structured to enable the stable retrieval, com-
parison and querying of results. The existing sources vary
widely in terms of data set size, available user interface,
experimental protocol or sample details, choices of pro-
tein identifiers, linking to peptide evidence from MS
experiments, MS search software used, and extent of data
annotation. This information needs to be compiled fur-
ther and assembled for end users before they can consider
incorporating human plasma proteome data into their
studies. The largest single source of data is from an inde-
pendently conducted experimental study that utilized a
ion-mobility spectrometry (IMS) platform to chart the
existence of 9,087 proteins based on 37,842 unique
inferred peptide sequences, of which 2,928 proteins are
high-confidence [6]. There is not however a web-based
interface or other online resource for making this data
widely available. The other sources of data we examined
have some form of online presentation (aside from publi-
cation) and range in size from less than one thousand to
over several thousand identified proteins. The Plasma
Proteome Database (PPD) provides a web interface and is
geared for providing detailed functional annotations of
3,778 distinct proteins based on data extracted from the
literature, yet the PPD provides information on neither
experimental protocol or associated MS-detected peptides
used for protein identification [7]. HUPO PPP informa-
tion consists of 3,020 proteins and 47,950 peptides along
with experimental protocol information and is available
to the public online, but the data is only accessible as flat
files [8]. The Institute of Systems Biology (ISB) has sur-
veyed and analyzed a comparably smaller set of data pro-
duced by 28 human plasma proteomics experiments, and
has reported an approximate count of 960 proteins based
on the 6,929 distinct observed peptides in their web-inter-
faced PeptideAtlas database [3]. Another resource, provid-
ing evidence for human proteomics based mainly on data
from HUPO PPP, is hosted by the Global Proteome
Machine Organization (GPMO). An important feature of
the GPMO database is that it provides annotated informa-
tion to assist with the difficult process of validating pep-
tide MS/MS spectra and patterns of protein coverage [4].
GPMO also includes data from non-human organisms
such as cats, guinea pigs, rabbits, unicellular eukaryotes
like yeasts, as well as a number of prokaryotic organisms.
By gathering the protein and peptide data used to charac-
terize the proteome of a healthy individual, we made an
attempt to develop a resource that presents a comparative
baseline of plasma proteomics results against which pro-
teomic data from patients with diseases such as cancer,
neurodegenerative diseases, metabolic diseases, and other
genetic disorders may be studied. In this effort, we define
"healthy" or "normal" as human adults without major
known life-threatening diseases, genetic diseases, HIV, or
inflammation at the time of blood drawing (a slightly
more stringent variation than the HUPO definition in
Omenn et al. [5]). On these premises, we developed an
integrated database HIP2 (Healthy Human Individual's
Integrated Plasma Proteome) by compiling all of the exist-
ing experimental data performed on healthy individualBMC Medical Genomics 2008, 1:12 http://www.biomedcentral.com/1755-8794/1/12
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samples, and creating a web-based interface to aid the
many upcoming projects of protein biomarker studies of
health and disease [9]. With HIP2, clinical samplings of
patient plasma may be better compared to random or
non-random aspects of overlap with the reported set of
healthy human plasma proteins.
Construction and content
We collected 3,020 proteins and 47,950 peptides from
HUPO PPP in text format [5]; 9,087 proteins and 37,842
peptides from David Clemmer's group (DCG) recent pub-
lication supplemental material (in PDF format) [6]; 788
proteins and 6,039 peptides from PeptideAtlas (through
successive querying of the web interface) [3] and 1,175
proteins from Leigh Anderson's group (LAG) (in PDF for-
mat) [10]. HUPO contain two datasets: i) a dataset con-
sisting of 3,020 proteins, and ii) a dataset consisting of
9,504 proteins. In our case, we included the high confi-
dence core dataset of 3,020 proteins, where there are two
or more peptide hits. HUPO datasets come from 35 col-
laborating laboratories, and for the single-peptide hits in
the second data set, the number of laboratories can itself
introduce high amounts of noise from diverse laboratory
procedures and MS platforms, potentially acting to reduce
value of the data resource for large-scale interpretation. In
contrast, the single-peptide hits used in HIP2 come from a
single laboratory source, DCG. The uniformity attributa-
ble to this single laboratory source (and single MS plat-
form) merited inclusion of all 9,087 proteins coming
from this group. Data from the PeptideAtlas database
were also included, but was filtered to only include those
with publicly available experimental details. The integra-
tion of data from different resources is a non-trivial bioin-
formatics task, because the data sets are not standardized
syntactically or semantically. To resolve syntactic incom-
patibility, we wrote perl programs and converted all the
original data sets into comma-delimited files, and loaded
them into an Oracle 10G database server as staging tables.
To resolve semantic incompatibility, we developed a data
model first as shown in Fig. 1, and then converted all the
incompatible identifiers to standard IPI accession num-
bers [11], using a mapping table downloaded from
BioMart [12]. HUPO PPP and PeptideAtlas proteins are
indexed with IPI accession numbers, whereas the other
sources of data are indexed with other types of identifiers
such as Swiss-Prot accession numbers and RefSeq IDs.
Correspondence with other identifiers was achieved for
some of the text-based sources by parsing the sequence
header data inside FASTA files, and the integrity of the
mapping has been validated through comparisons of ref-
erenced sequences. A subset of 247 proteins from the LAG
data set did not have correspondence with IPI accession
numbers, and this subset was excluded from comparisons
between the four sources of data. The set of 788 proteins
from PeptideAtlas represents a subset of unique proteins
from a larger set of 960 proteins. The data from DCG con-
tains multiple splice variants labeled by numbers
appended to Swiss-Prot identifier strings, and the first
enumerated variant was found to map to the IPI accession
number in all cases. Table 1 presents a union built from
Relational data model schema for the table Figure 1
Relational data model schema for the table. Protein, peptide evidence, MS Experiment and sample.BMC Medical Genomics 2008, 1:12 http://www.biomedcentral.com/1755-8794/1/12
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the four sources of data used in HIP2, and also categorizes
proteins in terms of MS-based detection platform and
search software.
We show the overall design of the database in Fig. 2. Que-
ries from web site users are connected to a backend rela-
tional Oracle 10G database hosted at Indiana University's
High-Performance Computing Facility. The web interface
and database connectivity was implemented with PHP
and perl. The HIP2 web interface outputs results for user
queries into three different types of web pages: protein
pages, peptide pages, and experimental information
pages. The database result pages are also linked to external
web pages (see details on the "Help" section of the HIP2
database home site). The protein information page pro-
vides information as to whether a protein is in the healthy
human individual's plasma proteome, what function it
has, what peptides can be mapped to the protein, and
how the peptides are aligned according to trypsin diges-
tion criteria [13]. The HIP2  protein-peptide alignment
map highlights potential trypsin cleavage sites in red.
Identified peptides are displayed in green and are aligned
underneath the corresponding sequence in the protein.
The peptide information page provides peptide summa-
ries, experimental evidence and the aforementioned pep-
tide-protein alignment maps. Peptide summaries provide
information about the amino acid sequence length, a link
to the PeptideAtlas database for each peptide, and a link
to the Statistical Analysis of Protein Sequences server [14]
for researchers interested in peptide compositional pat-
terns. The experimental information page contains addi-
tional details about the experiment whenever disclosed
including the human subject's ethnic group, gender, sam-
ple preparation method, protein separation, material
type, peptide separation, depletion method, and reduc-
tion method (treatment of indoacetamide). HIP2  also
includes information on material type to distinguish
plasma and serum. We plan to develop an automated web
interface for future data contributions, using a standard
data submission format that is compliant with the
upcoming MIAPE proteomics standards [15].
The overall design of the HIP2 database Figure 2
The overall design of the HIP2 database. 1 = Query of 
protein "X" observed in plasma proteome; 2 = Query of pep-
tide "Y" observed in plasma proteome; 3 = Output result of 
"X" protein page ; 4 = Link to external database; 5 = Link to 
experimental page of protein "X"; 6 = Link to the peptide 
page of the protein "X"; 7 = Output result of peptide "Y"; 8 = 
Iterative query from peptide page to search for other pro-
teins associated with the peptide "Y".
Table 1: Summary of HIP2 database. The numbers of peptides and proteins represent unique entries that are the union of multiple 
subjects, possibly from different ethnic groups.
Source Platform Peptides Proteins Search Software
HUPO PPP (3,020 proteins and 47,950 peptides) ESI-MS/MS_DECA 712 348 SEQUEST
ESI-MS/MS_DECAXP 5796 2149 SEQUEST
ESI-MS/MS_LCQ 1818 427 SEQUEST/SONAR
ESI-MS/MS_QSTAR 309 137 SEQUEST
ESI-MS/MS_QTOF 5078 573 MASCOT
ESI-MS/MS_QTRAP 195 51 MASCOT
MALDI_MS/MS_QSTAR 384 60 SEQUEST/MASCOT
David Clemmer's group (9,087 proteins and 37,842 peptides) IMS_MS/MS_TOF 35781 9,087 MASCOT
PeptideAtlas (788 proteins and 6,039 peptides) ESI-MS/MS_DECA 260 110 SEQUEST
ESI-MS/MS_DECAXP 317 159 SEQUEST
ESI-MS/MS_LCQ 1101 263 SEQUEST
ESI-MS/MS_QSTAR 14 14 SEQUEST
ESI-MS/MS_QTOF 728 215 SEQUEST
LC_MS/MS* 1153 250 SEQUEST
Leigh Anderson's group (1,175 proteins) 2DEMS & LC_MS/MS* ---- 928 SEQUEST
*Not definedBMC Medical Genomics 2008, 1:12 http://www.biomedcentral.com/1755-8794/1/12
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Utility and discussion
The HIP2 database provides protein biologists and clinical
biomedical researchers with a new gateway for exploring
proteins from the human proteome with peptide-level
evidence found in plasma. The basic questions that the
HIP2  database helps biological researchers answer
includes "whether a protein may be found in human
plasma" and "how likely or easily it is for a protein to be
observed in healthy human plasma with mass spectrome-
try." The HIP2 database allows its users to assess the confi-
dence of identifying plasma proteins in "normal" plasma
MS proteomics experiments by examining such evidence
as the number of matched peptide hits, data sources cov-
ered, MS experiments observed, types of MS platforms,
and search software used. The protein and peptide
sequence information also enables the user to examine
peptide evidence that may be mapped to different gene
splice variants and protein isoforms. Partial protein
trypsin digestions can be evaluated based on multiple
peptide to protein alignment information presented in
the database. The overall quality of digested peptide
mapped to proteins can be further used by mass spectrom-
etry data analysts to assess different performance of MS
proteomics platforms or samples. A typical example in the
HIP2 database of a protein-peptide sequence comparison
is how the peptide sequence
'KQSAGLVLWGAILFVAWNALLLLFFWTRPAPGRPPS-
VSALDGDPASLTR' is present in two proteins,
IPI00000138 and IPI00179044, and aligns with the same
sites of trypsin cleavage (as shown in Fig. 6). In the case of
protein IPI00000138, evidence for the protein was found
in three data sources, three MS experiments, three MS
platforms, two MS search software and six mapped pep-
tide sequences, whereas in the case of protein
'IPI00179044', there are not any experimentally proven
peptides from MS results.
The HIP2 database has been mapped to cover a significant
portion of the human proteome, which can be retrieved
by user queries of plasma proteins or peptides, with full
MS experimental context and detailed peptide-to-protein
mapping relationships. As of the latest version (Feb
2008), the HIP2 database aggregates information from 14
different protein separation/MS analytical platforms, 63
different samples, and 6 different types of MS search soft-
ware. The HIP2 database provides associated identifica-
tions of 12,787 protein entries representing 11,588
unique proteins covering 17% of all 67,511 proteins in
the human IPI database [11]. Over 77% of the proteins
included are identified from two or more different peptide
sequences as shown in Fig. 3, where identification is
defined by both peptide detection and a protein sequence
match. We observed that almost 24% of the proteins
included have been identified from two or more experi-
mental platforms as shown in Fig. 4, while only 106 pro-
teins (<1%) are identified by all four sources, implicating
substantial variation in protein detections caused by a
number of factors including experimental parameters and
subject-to-subject variation (Fig. 5). Finding detailed
instances of experimental detection of proteins by experi-
mentally proven peptides is necessary to evaluate future
options for experimental detection. For biostatisticians,
the HIP2 database can be a supplemental resource for
assessing the likelihood of observing different peptides of
the same plasma proteins from different platforms. Our
resource is also useful to computational proteomics
researchers, since we enable navigation among various
ranges of association between a peptide sequence and a
candidate protein sequence; this information may be val-
uable for assigning probabilistic confidence of all human
proteins, whether or not they have been experimentally
observed in human plasma [16]. The study of how search
software is used in the experimental protocol, especially
for how sequence alignment and locations of potential
tryptic cleavage sites (highlighted by the HIP2 interface)
influence peptide detection, can now be directly
addressed by the proteomics community. This online
HIP2 database can be a valuable source of information to
biomedical researchers as they interpret proteomics pro-
file changes in patients' plasma and pursue biomarker dis-
covery.
Conclusion
The primary goal of the HIP2 database is to support future
clinical proteomics research, especially the discovery of
biomarkers through plasma proteomics profiling. For bio-
medical researchers interested in MS-based plasma
biomarker studies, HIP2 can be the first database to search
against a list of candidate proteins/genes or peptides
before choices of prioritized biomarker candidates are
made. As the database grows, additional annotation infor-
mation of human plasma proteins such as relative abun-
dance, normal range of variability, detectability,
peptidomic patterns associative with cleavage, mutation
and putative sites of glycosylation will be added. HIP2
helps provide an integrated interface where database cura-
tors and data contributors can work together to collect
ongoing published data from healthy human plasma pro-
teomics experiments, foster community-based assessment
of presence and absence of proteins in healthy human
plasma, and provide a centralized data repository for sub-
sequent bioinformatics analysis of the consistency and
biases of each MS proteomics platform or search software.
We expect this database to become an essential clinical
proteomics resource, helping link together the commu-
nity of biomedical researchers engaged in biomarker stud-
ies and the community of mass spectrometry researchers
developing sensitive analytical solutions.BMC Medical Genomics 2008, 1:12 http://www.biomedcentral.com/1755-8794/1/12
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Availability and requirements
The online content of HIP2 is freely available to all WWW
users. The database infrastructure and software tools used
to develop the database are subject to the intellectual
property protection terms of Indiana University.
Project name: Database for Healthy Human Individual's
Integrated Plasma Proteome
Project home page: HIP2 website [17]
Browser requirements: Modern browsers (e.g., Firefox or
Microsoft Explorer) will function satisfactorily.
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Overlapping of plasma proteins identified from different  sources Figure 5
Overlapping of plasma proteins identified from dif-
ferent sources. C = Clemmer's group; H = HUPO PPP ; L 
= Leigh Anderson's group; P = PepAtlas data source.
Protein identification Figure 3
Protein identification. Number of proteins (Y axis) versus the number of distinct peptides used for the protein identification 
(X axis).
Total proteins categorized by the number of platforms that  identify them Figure 4
Total proteins categorized by the number of plat-
forms that identify them. Numbers in the legend refer to 
the number of platforms.BMC Medical Genomics 2008, 1:12 http://www.biomedcentral.com/1755-8794/1/12
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